Advertisement
Letter to the Editor| Volume 107, P113-115, January 2023

Characteristics of JAK2 unmutated erythrocytosis: Distinctive traits between polycythemia vera and non-polycythemia vera patients

  • Vincent Ernest
    Affiliations
    Laboratory of Hemostasis, Assistance Publique-Hôpitaux de Marseille (AP-HM), CHU La Timone, Marseille, France
    Search for articles by this author
  • Norman Abbou
    Affiliations
    Biochemistry and Molecular Biology Laboratory, Assistance Publique-Hôpitaux de Marseille (AP-HM), CHU NORD, Marseille, France
    Search for articles by this author
  • Antoine Tichadou
    Affiliations
    Hematology and Cellular Therapy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), CHU La Conception, Marseille, France
    Search for articles by this author
  • Robin Arcani
    Correspondence
    Corresponding author at: Internal Medicine and Therapeutics Department, CHU La Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.
    Affiliations
    Internal Medicine and Therapeutics Department, CHU La Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France

    Center for Cardiovascular and Nutrition Research (C2VN), INRA 1260, INSERM UMR_S 1263, Aix-Marseille University, Marseille, France
    Search for articles by this author
  • Geoffroy Venton
    Affiliations
    Hematology and Cellular Therapy Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), CHU La Conception, Marseille, France
    Search for articles by this author
Published:September 09, 2022DOI:https://doi.org/10.1016/j.ejim.2022.09.004
Characteristics of JAK2 unmutated erythrocytosis: Distinctive traits between polycythemia vera and non-polycythemia vera patients
Previous ArticleLong-standing thrombocytosis often precedes thromboembolic complications heralding the diagnosis of essential thrombocythemia
Next ArticleFor whom the bell tolls: Attacks on Ukrainian healthcare threatens us all
      Polycythemia is a frequent reason for consultation, and is related to various etiologies. Erythropoietin (EPO) plays a major role in the physiological stimulation of red blood cell (RBC) progenitors’ differentiation and proliferation. EPO production depends on Hypoxia-Inducible Factors (HIF), which are oxygen-sensitive [
      • Haase V.H.
      Regulation of erythropoiesis by hypoxia-inducible factors.
      Blood Rev. 2013; 27: 41-53https://doi.org/10.1016/j.blre.2012.12.003
      ]. In hypoxia conditions, stabilized HIF-2A promotes expression of the EPO gene. EPO binds to the EPO-receptor (EPOR) at the surface of RBC progenitors, thus stimulating their expansion [
      • Tóthová Z.
      • Tomc J.
      • Debeljak N.
      • Solár P.
      STAT5 as a key protein of erythropoietin signalization.
      Int J Mol Sci. 2021; 22: 7109https://doi.org/10.3390/ijms22137109
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Haase V.H.
        Regulation of erythropoiesis by hypoxia-inducible factors.
        Blood Rev. 2013; 27: 41-53https://doi.org/10.1016/j.blre.2012.12.003
        View in Article
        • Tóthová Z.
        • Tomc J.
        • Debeljak N.
        • Solár P.
        STAT5 as a key protein of erythropoietin signalization.
        Int J Mol Sci. 2021; 22: 7109https://doi.org/10.3390/ijms22137109
        View in Article
        • Gangat N.
        • Szuber N.
        • Pardanani A.
        • Tefferi A.
        JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.
        Leukemia. 2021; 35: 2166-2181https://doi.org/10.1038/s41375-021-01290-6
        View in Article
        • Barbui T.
        • Thiele J.
        • Gisslinger H.
        • Kvasnicka H.M.
        • Vannucchi A.M.
        • Guglielmelli P.
        • et al.
        The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
        Blood Cancer J. 2018; 8: 15https://doi.org/10.1038/s41408-018-0054-y
        View in Article
        • Spivak J.L.
        How i treat polycythemia vera.
        Blood. 2019; 134: 341-352https://doi.org/10.1182/blood.2018834044
        View in Article
        • McMullin M.F.
        • Harrison C.N.
        • Ali S.
        • Cargo C.
        • Chen F.
        • Ewing J.
        • et al.
        A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.
        Br J Haematol. 2019; 184: 176-191https://doi.org/10.1111/bjh.15648
        View in Article
        • Tefferi A.
        • Barbui T.
        Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
        Am J Hematol. 2020; 95: 1599-1613https://doi.org/10.1002/ajh.26008
        View in Article
        • Landolfi R.
        • Marchioli R.
        • Kutti J.
        • Gisslinger H.
        • Tognoni G.
        • Patrono C.
        • et al.
        Efficacy and safety of low-dose aspirin in polycythemia vera.
        N Engl J Med. 2004; 350: 114-124https://doi.org/10.1056/NEJMoa035572
        View in Article
        • Michiels J.J.
        • Berneman Z.
        • Schroyens W.
        • Koudstaal P.J.
        • Lindemans J.
        • Neumann H.A.M.
        • et al.
        Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
        Platelets. 2006; 17: 528-544https://doi.org/10.1080/09537100600758677
        View in Article
        • Rumi E.
        • McMullin M.F.
        • Harrison C.
        • Ellis M.H.
        • Barzilai M.
        • Sarid N.
        • et al.
        Facing erythrocytosis: results of an international physician survey.
        Am J Hematol. 2019; 94: E225-E227https://doi.org/10.1002/ajh.25545
        View in Article

      Article info

      Publication history

      Published online: September 09, 2022
      Accepted: September 6, 2022
      Received in revised form: September 1, 2022
      Received: August 4, 2022

      Identification

      DOI: https://doi.org/10.1016/j.ejim.2022.09.004

      Copyright

      © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX